financetom
Business
financetom
/
Business
/
Ubiquiti beats Q1 revenue estimates, declares dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ubiquiti beats Q1 revenue estimates, declares dividend
Nov 7, 2025 4:35 AM

Overview

* Ubiquiti ( UI ) fiscal Q1 revenue grows 33.3% yr/yr, beating analyst expectations

* Adjusted EPS for fiscal Q1 beats consensus, driven by higher revenues and gross profit

* Company declares $0.80 per share cash dividend, payable November 24, 2025

Outlook

* Ubiquiti ( UI ) did not provide specific guidance for future quarters or the full year

Result Drivers

* ENTERPRISE TECHNOLOGY - Revenue from Enterprise Technology platform increased, driving overall revenue growth

* GROSS MARGIN IMPROVEMENT - Higher gross margins due to favorable product mix and lower shipping costs, partially offset by higher tariff costs

* INCREASED R&D EXPENSES - Higher R&D expenses driven by increased employee-related costs and depreciation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $733.80 $635.10

Revenue mln mln (2

Analysts

)

Q1 Beat $3.46 $2.92 (1

Adjusted Analyst)

EPS

Q1 EPS $3.43

Q1 $209.30

Adjusted mln

Net

Income

Q1 Gross 46.00%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the communications & networking peer group is "buy."

* Wall Street's median 12-month price target for Ubiquiti Inc ( UI ) is $509.50, about 49.1% below its November 6 closing price of $759.57

* The stock recently traded at 62 times the next 12-month earnings vs. a P/E of 47 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump sows confusion on tariffs for Canada and Mexico, floats 25% duty on EU goods
Trump sows confusion on tariffs for Canada and Mexico, floats 25% duty on EU goods
Feb 26, 2025
* Trump says Canada, Mexico tariffs take effect on April 2 * White House official says Trump to review March 4 deadline * Trump says tariffs on EU auto imports to be generally 25% * Senate confirms Jamieson Greer as U.S. Trade Representative (Adds comments from Canadian, Mexican officials, paragraphs 6-8, European Commission spokesperson, paragraphs 16-17) By David Lawder and...
Vista Energy Q4 Adjusted Earnings Decline, Revenue Rises
Vista Energy Q4 Adjusted Earnings Decline, Revenue Rises
Feb 26, 2025
05:36 PM EST, 02/26/2025 (MT Newswires) -- Vista Energy (VIST) reported Q4 adjusted earnings late Wednesday of $0.23 per diluted share, down from $2.52 a year earlier. One analyst polled by FactSet, on average, expected a loss of $0.90. Revenue for the quarter ended Dec. 31 was $471.3 million, compared with $309.2 million a year earlier. Analysts expected $457.1 million....
Ovintiv Q4 Non-GAAP Adjusted Earnings Fall; Dividend Maintained
Ovintiv Q4 Non-GAAP Adjusted Earnings Fall; Dividend Maintained
Feb 26, 2025
05:35 PM EST, 02/26/2025 (MT Newswires) -- Ovintiv ( OVV ) reported Q4 non-GAAP adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.35 a year earlier. Analysts polled by FactSet expected $1.13. The company announced a 2025 capital program of $2.15 billion to $2.25 billion. Ovintiv ( OVV ) maintained its quarterly dividend at $0.30 a share,...
Acadia Pharmaceuticals Q4 EPS, Revenue Rise
Acadia Pharmaceuticals Q4 EPS, Revenue Rise
Feb 26, 2025
05:35 PM EST, 02/26/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) reported Q4 earnings Wednesday of $0.86 per diluted share, up from $0.28 a year earlier. Analysts polled by FactSet expected $0.22. Revenue for the quarter ended Dec. 31 was $259.6 million, up from $231 million a year earlier. Analysts surveyed by FactSet expected $255.6 million. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved